Iambic Therapeutics Files 424B4 Prospectus for Its IPO

Key takeaways

• Iambic Therapeutics, Inc. filed a 424B4 prospectus with the SEC on Oct. 15, 2026. That is the final-prospectus form companies use once an offering has been priced.
• The filing is large, listed at 46 MB on EDGAR, so the full terms sit in the document itself and deserve a line-by-line read.
• Separately, Frazier Life Sciences Acquisition Corp. II (FLSC) filed an 8-K on the same day that matched a search for the closing of its initial public offering.
• Both filings point to continued life-sciences activity in the public-offering pipeline this week.

What was filed

According to EDGAR, Iambic Therapeutics filed its 424B4 at 4:05 p.m. Eastern on Thursday, Oct. 15, 2026, under accession number 0001193125-26-422865. The 424B4 is the prospectus a company files after pricing, and it carries the final terms of the deal. In an initial public offering, those include the price per share, the number of shares sold and the underwriting arrangements.

Item	Detail
Filer	Iambic Therapeutics, Inc.
Form	424B4 (final prospectus)
Filed	Oct. 15, 2026
File size	46 MB

Why the 424B4 prospectus matters for IPO pricing

The 424B4 is where the pricing story becomes official. Earlier registration drafts typically carry a price range or placeholders. The final document replaces those with the numbers that investors actually received. Readers reviewing IPO pricing usually compare the final terms with the earlier range to see whether a deal was set at, above or below expectations.

Other sections are worth checking in the same pass. The use-of-proceeds section shows how the company plans to spend the money. The capitalization and dilution tables show how new shares change ownership. The underwriting section lays out the banks’ compensation and any lock-up terms that govern when existing holders may sell.

For a company with “Therapeutics” in its name, the risk factors and the description of its development programs are also central to the filing. They set out what the business depends on and what could go wrong, and they are the primary reference for anyone assessing the valuation implied by the offering.

A SPAC closing the same day

A different kind of offering surfaced in the same filing window. Frazier Life Sciences Acquisition Corp. II, which trades under the ticker FLSC, filed an 8-K on Oct. 15 that matched a search for the closing of its initial public offering. A SPAC, or blank-check company, raises money in its IPO with the aim of later merging with a private business, and the closing 8-K is typically where it reports that the offering has settled.

The two filings differ in structure. Iambic is an operating company selling shares in a conventional IPO. FLSC is a shell vehicle whose value depends on finding a deal. Both are tied to the life-sciences sector, though, and they show that issuers in the space are using more than one route to the public markets.

What to watch next

• Trading debut. Once shares begin trading, first-day performance shows how the market received the final terms.
• Underwriter options. Filings after the pricing may show whether any over-allotment option was exercised.
• Closing filings. An 8-K or similar report typically confirms when the offering has settled and the proceeds have been received.
• SPAC next steps. For FLSC, the relevant markers are its trust arrangements and the deadline by which it must complete a business combination, both of which are laid out in its own offering documents.
• First reports. New public companies move quickly into quarterly reporting, so the first earnings disclosures will be the next full look at their finances.

Readers should rely on the filings themselves for the final numbers rather than secondary summaries. This article is a report on public filings, not investment advice.